Literature DB >> 19016909

Human CD4low CD25high regulatory T cells indiscriminately kill autologous activated T cells.

Ewa Bryl1, Agnieszka Daca, Agnieszka Jóźwik, Jacek M Witkowski.   

Abstract

The interest of the scientific community in regulatory CD4(+) T cells has reached an enormously high level. Common agreement is that they inhibit not only the proliferation of CD4 and CD8 lymphocytes, but also the activities of natural killer cells and macrophages. However, very important issues concerning actual mechanism(s) and specificity of the action of regulatory T cells (Tregs) upon responder cells are still unsolved or vague. The best known marker for Tregs is the expression of transcription factor FoxP3, widely used for their enumeration. It is known that FoxP3 inhibits cytokine production so the most probable action of Tregs is direct. However, FoxP3 expression cannot be used for functional studies in humans. Therefore we identified human peripheral blood Tregs as a distinct, very well-defined population of peripheral blood T cells with reduced CD4 and high CD25 expression (CD4(low) CD25(high)), which fulfils the current phenotypic criteria identifying the Tregs by simultaneously expressing high amounts of FoxP3. We conclude that the definition of a CD4(low) CD25(high) phenotype is enough to unambiguously detect and study the regulatory function of these cells. On the functional level, the CD4(low) Tregs are able to non-specifically suppress the proliferation of autologous, previously polyclonally activated CD4(+) and CD4(-) lymphocytes and to kill them by direct contact, probably utilizing intracellular granzyme B and perforin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19016909      PMCID: PMC2753935          DOI: 10.1111/j.1365-2567.2008.02961.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

Review 1.  Regulatory T cells: key controllers of immunologic self-tolerance.

Authors:  S Sakaguchi
Journal:  Cell       Date:  2000-05-26       Impact factor: 41.582

Review 2.  Suppressor T cells--they're back and critical for regulation of autoimmunity!

Authors:  L Chatenoud; B Salomon; J A Bluestone
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

3.  Age-related increase of frequency of a new, phenotypically distinct subpopulation of human peripheral blood T cells expressing lowered levels of CD4.

Authors:  E Bryl; M Gazda; J Foerster; J M Witkowski
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

4.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

Review 5.  Generation and function of antigen-specific suppressor and regulatory T cells.

Authors:  Nicole Suciu-Foca; John S Manavalan; Raffaello Cortesini
Journal:  Transpl Immunol       Date:  2003 Jul-Sep       Impact factor: 1.708

6.  Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population.

Authors:  L S Taams; J Smith; M H Rustin; M Salmon; L W Poulter; A N Akbar
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

7.  Formation of the killer Ig-like receptor repertoire on CD4+CD28null T cells.

Authors:  Melissa R Snyder; Lars-Olof Muegge; Chetan Offord; William M O'Fallon; Zeljko Bajzer; Cornelia M Weyand; Jörg J Goronzy
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

8.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

9.  An essential role for Scurfin in CD4+CD25+ T regulatory cells.

Authors:  Roli Khattri; Tom Cox; Sue-Ann Yasayko; Fred Ramsdell
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

10.  The control of CD4+CD25+Foxp3+ regulatory T cell survival.

Authors:  Pushpa Pandiyan; Michael J Lenardo
Journal:  Biol Direct       Date:  2008-02-27       Impact factor: 4.540

View more
  7 in total

1.  Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity.

Authors:  J Pawłowska; Z Smoleńska; A Daca; J M Witkowski; E Bryl
Journal:  Clin Exp Immunol       Date:  2010-12-13       Impact factor: 4.330

2.  Hsp40 proteins modulate humoral and cellular immune response in rheumatoid arthritis patients.

Authors:  Stefan Tukaj; Agnieszka Kotlarz; Agnieszka Jozwik; Zaneta Smolenska; Ewa Bryl; Jacek M Witkowski; Barbara Lipinska
Journal:  Cell Stress Chaperones       Date:  2010-02-02       Impact factor: 3.667

3.  Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly.

Authors:  Agnieszka Jóźwik; Jerzy Landowski; Leszek Bidzan; Tamas Fülop; Ewa Bryl; Jacek M Witkowski
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

4.  Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors.

Authors:  Agnieszka Cegielska; Katarzyna A Lisowska; Alicja Dębska-Ślizień; Beata Imko-Walczuk; Aleksandra Okuniewska; Bolesław Rutkowski
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

Review 5.  Immunosenescence and COVID-19.

Authors:  Jacek M Witkowski; Tamas Fulop; Ewa Bryl
Journal:  Mech Ageing Dev       Date:  2022-04-01       Impact factor: 5.498

6.  Influence of hemodialysis on circulating CD4(low)CD25 (high) regulatory T cells in end-stage renal disease patients.

Authors:  Katarzyna A Lisowska; Alicja Dębska-Ślizień; Aleksandra Jasiulewicz; Ewa Bryl; Jacek M Witkowski
Journal:  Inflamm Res       Date:  2013-11-05       Impact factor: 4.575

7.  Immunomodulatory effect of standardized C. asiatica extract on a promotion of regulatory T cells in rats.

Authors:  Supannikar Tawinwung; Dhirarin Junsaeng; Supanut Utthiya; Phisit Khemawoot
Journal:  BMC Complement Med Ther       Date:  2021-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.